ArticlePloS one2014
Canine parvovirus VP2 protein expressed in silkworm pupae self-assembles into virus-like particles with high immunogenicity.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Review: A systematic review of virus-like particles of coronavirus: Assembly, generation, chimerism and their application in basic research and in the clinic.International journal of biological macromolecules · 2022Pooled it
- Emergence of canine parvovirus-2c in domestic cats and adaptive evolution of the NS1 gene: Molecular epidemiology of feline parvoviruses in Northern Vietnam (2022-2025).Veterinary world · 2026Article
- Advances in Feline Panleukopenia Virus Vaccines: Immunological Mechanisms, Current Challenges, and Future Perspectives.Viruses · 2026Review
- Development and Validation of a Recombinant VP2-Based Indirect ELISA for Canine Parvovirus.Microorganisms · 2026Article
- Exploring an Aptamer-Based Approach to Assess Canine Parvovirus Integrity After Disinfection Treatment.Viruses · 2025Article
- Effects of Canine IL-12 on the Immune Response Against the Canine Parvovirus VP2 Protein.Vaccines · 2025Article
- Virus-like Particle Vaccine for Feline Panleukopenia: Immunogenicity and Protective Efficacy in Cats.Vaccines · 2025Article
- Identification of Host-Protein Interaction Network of Canine Parvovirus Capsid Protein VP2 in F81 Cells.Microorganisms · 2025Article
- Parvoviruses NS1 oncolytic attributes: mechanistic insights and synergistic anti-tumor therapeutic strategies.Frontiers in microbiology · 2025Review
- Immunoinformatics for Novel Multi-Epitope Vaccine Development in Canine Parvovirus Infections.Biomedicines · 2023Article
- Display of multiple proteins on engineered canine parvovirus-like particles expressed in cultured silkworm cells and silkworm larvae.Frontiers in bioengineering and biotechnology · 2023Article
- Characterization of the VP2 and NS1 genes from canine parvovirus type 2 (CPV-2) and feline panleukopenia virus (FPV) in Northern China.Frontiers in veterinary science · 2022Article
- Self-assembled raccoon dog parvovirus VP2 protein confers immunity against RDPV disease in raccoon dogs: in vitro and in vivo studies.Virology journal · 2021Article
- Recovery of Recombinant Canine Distemper Virus That Expresses CPV-2a VP2: Uncovering the Mutation Profile of Recombinant Undergoing 50 Serial PassagesFrontiers in cellular and infection microbiology · 2021Article
- Study of the immunogenicity of the VP2 protein of canine parvovirus produced using an improved Baculovirus expression system.BMC veterinary research · 2020Article
- Large-scale manufacture of VP2 VLP vaccine against porcine parvovirus in Escherichia coli with high-density fermentation.Applied microbiology and biotechnology · 2020Article
- Construction and Immunogenicity of Virus-Like Particles of Feline Parvovirus from the Tiger.Viruses · 2020Article
- Edible Vaccines: Promises and Challenges.Molecular biotechnology · 2020Review
- Oral administration of porcine epidemic diarrhea virus spike protein expressing in silkworm pupae failed to elicit immune responses in pigs.AMB Express · 2020Article
- Alternative Methods of Vaccine Delivery: An Overview of Edible and Intradermal Vaccines.Journal of immunology research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The VP2 structural protein of parvovirus can produce virus-like particles (VLPs) by a self-assembly process in vitro, making VLPs attractive vaccine candidates. In this study, the VP2 protein of canine parvovirus (CPV) was expressed using a baculovirus expression system and assembled into parvovirus-like particles in insect cells and pupae. Electron micrographs of VLPs showed that they were very similar in size and morphology when compared to the wild-type parvovirus. The immunogenicity of the VLPs was investigated in mice and dogs. Mice immunized intramuscularly with purified VLPs, in the absence of an adjuvant, elicited CD4(+) and CD8(+) T cell responses and were able to elicit a neutralizing antibody response against CPV, while the oral administration of raw homogenates containing VLPs to the dogs resulted in a systemic immune response and long-lasting immunity. These results demonstrate that the CPV-VLPs stimulate both cellular and humoral immune responses, and so CPV-VLPs may be a promising candidate vaccine for the prevention of CPV-associated disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.